What it's for (Indications)
- Montelukast + Fexofenadine combination therapy is indicated for the symptomatic relief of seasonal and perennial allergic rhinitis in patients for whom combined therapy is appropriate.
- This includes conditions where both an anti-leukotriene agent and a non-sedating H1-antihistamine are deemed necessary to manage symptoms effectively.
- Symptoms typically include sneezing, rhinorrhea, nasal congestion, pruritus of the nose, palate, throat, and eyes, as well as watery eyes.
- This combination is particularly beneficial for patients whose allergic rhinitis is inadequately controlled by monotherapy with either an antihistamine or a leukotriene receptor antagonist alone, or those who require the comprehensive anti-inflammatory and anti-allergic effects provided by both active ingredients.
- It targets both the immediate hypersensitivity reactions and the later-phase inflammatory processes associated with allergic conditions.
- The use should be guided by a thorough clinical assessment, considering the patient's specific symptom profile and response to prior treatments.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of Montelukast + Fexofenadine typically involves oral administration once daily. The specific strength prescribed will depend on the patient's age, weight, and the severity of their symptoms, adhering to established guidelines for each individual component. For adults and adolescents 12 years of age and older, a common strength is Montelukast 10 mg combined with Fexofenadine 120 mg or 180 mg, taken once daily. The tablet should be swallowed whole with water, and it is generally advised to avoid taking it with fruit juices (such as grapefruit, orange, and apple juice) as these can significantly reduce the bioavailability of fexofenadine. Administration should preferably be done on an empty stomach or at least one hour before or two hours after a meal to maximize fexofenadine absorption. Dosage adjustments may be necessary for patients with renal impairment; however, specific recommendations for the combination product should be sought from the prescribing information or a healthcare professional, as renal function primarily affects fexofenadine clearance. It is crucial not to exceed the prescribed dose, and the treatment duration should be determined by a physician based on the clinical response and symptom control. |
Safety & Warnings
Common Side Effects
- The combination of Montelukast and Fexofenadine can lead to various side effects, reflecting the pharmacological profiles of both components.
- Common side effects reported by patients include headache, nausea, abdominal discomfort or pain, diarrhea, and dizziness.
- Upper respiratory tract infection symptoms, cough, and fatigue have also been observed.
- Specifically related to fexofenadine, mild drowsiness (less common than with first-generation antihistamines), dyspepsia, and dry mouth may occur.
- For montelukast, notable adverse effects include gastrointestinal disturbances, asthenia, fever, and rashes.
- Crucially, **montelukast has been associated with serious neuropsychiatric events**, including but not limited to agitation, aggressive behavior, anxiety, depression, disorientation, abnormal dreams, hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, suicidal ideation and behavior (including suicide), and tremor.
- Patients and caregivers should be vigilant for any changes in mood or behavior and report them promptly to a healthcare provider.
- While generally well-tolerated, rare but serious hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome, may also occur with either component, necessitating immediate medical attention.
Serious Warnings
- Black Box Warning: **WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS** Serious neuropsychiatric events have been reported with the use of montelukast, a component of Montelukast + Fexofenadine. These events include, but are not limited to, agitation, aggressive behavior, anxiety, depression, disorientation, abnormal dreams, hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism (sleepwalking), suicidal thoughts and behavior (including suicide), and tremor. The relationship between montelukast use and these events has been firmly established, prompting the issuance of this warning. Patients and caregivers should be advised to be vigilant for and immediately report any changes in behavior, mood, or other neuropsychiatric symptoms to a healthcare professional. Healthcare professionals should carefully weigh the benefits of Montelukast + Fexofenadine against the risk of neuropsychiatric events before prescribing, especially when considering its use for allergic rhinitis. For allergic rhinitis, Montelukast + Fexofenadine should be reserved for patients who have not responded adequately to alternative therapies or who experience intolerable side effects with other treatments. Continuous monitoring for neuropsychiatric symptoms is recommended during the entire course of treatment.
- Montelukast + Fexofenadine combination therapy requires careful consideration of several warnings to ensure patient safety and efficacy.
- This medication is **not indicated for the relief of acute asthma attacks**, including status asthmaticus; appropriate rescue medication should be available for such events.
- Patients should be instructed not to abruptly substitute this combination for inhaled or oral corticosteroids without consulting their physician, as this can lead to adrenal insufficiency or withdrawal symptoms.
- There is a potential for central nervous system (CNS) effects, including dizziness and fatigue, which may impair the ability to perform tasks requiring mental alertness, such as driving or operating heavy machinery, although fexofenadine is generally considered non-sedating at recommended doses.
- Caution is advised in patients with pre-existing cardiovascular disease due to the theoretical potential for QT interval prolongation with antihistamines, although fexofenadine has shown minimal cardiac effects in clinical trials.
- Patients with renal impairment should be monitored closely, as fexofenadine is primarily eliminated via the kidneys, and dosage adjustments may be necessary.
- Grapefruit, orange, and apple juices can reduce the bioavailability of fexofenadine, thus co-administration should be avoided.
- Healthcare providers should also be aware of potential drug interactions, particularly with antacids containing aluminum or magnesium hydroxide, which can decrease fexofenadine absorption.
- The emergence of new neuropsychiatric symptoms or worsening of existing ones should prompt immediate evaluation, given the known risks associated with montelukast.
How it Works (Mechanism of Action)
The therapeutic efficacy of Montelukast + Fexofenadine stems from the synergistic actions of its two distinct active pharmaceutical ingredients, targeting different pathways involved in allergic and inflammatory responses.
**Montelukast** operates as a selective and orally active leukotriene receptor antagonist. It specifically binds with high affinity to the cysteinyl leukotriene type 1 (CysLT1) receptor, thereby inhibiting the physiological actions of leukotrienes (LTC4, LTD4, LTE4). Cysteinyl leukotrienes are potent inflammatory mediators released from various cells, including mast cells and eosinophils, which contribute to the pathogenesis of allergic rhinitis and asthma by causing bronchoconstriction, increased vascular permeability, increased mucus secretion, and recruitment of inflammatory cells. By blocking these receptors, montelukast helps to alleviate symptoms such as nasal congestion, rhinorrhea, and sneezing, and reduces the underlying inflammation.
**Fexofenadine** is a selective peripheral H1-receptor antagonist. It is the pharmacologically active metabolite of terfenadine and is distinguished by its non-sedating profile due to its minimal penetration of the blood-brain barrier. Fexofenadine competitively antagonizes the binding of histamine to H1 receptors on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. Histamine, released during allergic reactions, is responsible for immediate hypersensitivity symptoms including pruritus, sneezing, watery eyes, and increased vascular permeability leading to edema. By blocking H1 receptors, fexofenadine effectively reduces these acute allergic manifestations without significant central nervous system depression. The combination thus provides comprehensive symptomatic relief by addressing both early-phase histamine-mediated reactions and late-phase leukotriene-mediated inflammation.
Commercial Brands (Alternatives)
No other brands found for this formula.